Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

Share Option Plan

14 Mar 2006 07:05

Cello Group plc14 March 2006 Cello Group PLC("Cello") New Performance Share Option Plan Introduction Cello has adopted a new Performance Share Option Plan. The RemunerationCommittee of Cello recently carried out a review of the long term incentivearrangements for executive directors and other senior employees. Following thereview the Committee concluded that the existing arrangements should be replacedby a new Performance Share Option Plan. Background Cello previously operated two share option plans, the Enterprise ManagementIncentive Plan 2004 ("the EMI Plan") and the Cello Unapproved Share Option Plan2004 ("the Unapproved Plan"). Under these two plans ("the original share plans")options were granted with an exercise price equal to the market price at thegrant date. Following its review the Remuneration Committee concluded that, going forward,market value share option plans were not the most appropriate vehicles throughwhich Cello's senior executives should be granted long term incentives andaccordingly, under the new Plan, options will be structured as conditionalawards over fully paid shares with an exercise price equal to the nominal valueof the shares, currently 10p per share. As relatively ungeared investments,awards under the Plan will more closely match the returns received byshareholders than is the case with market value share options. In addition,these awards are likely to provide a closer correlation between actual rewardlevels and accounting charges going forward, as well as being less dilutive thanmarket value options. In addition, directors and eligible employees who elect to receive up to 50% ofcash bonuses, net of tax and national insurance, in the form of Cello shareswill be granted a conditional award over an equal number of shares under thePlan. Subject to the individual's continued employment by Cello and ownership ofthe shares issued in lieu of bonus, the matching shares will vest after fouryears subject to the performance conditions having been met. Principal provisions of the Plan Individual limits. Awards of options over shares, excluding bonus matchingshares, worth no more than 150% of basic salary may be made each year. Therewill also be a limit on the cumulative number of shares, excluding bonusmatching shares, which may be awarded to any individual over the life of thePlan. This limit has been set at 500,000 shares. Overall dilution limit. The Plan will be subject to the existing overalldilution limit which applied to the original share plans and was set out in theAdmission Document at the time of Cello's admission to AIM in November 2004.Therefore, in any ten year period from the date of adoption of the originalshare plans no more than 15% of the issued ordinary share capital of the companyfrom time to time may in aggregate be allocated under any share schemes operatedby the company. Performance conditions. Options will be exercisable four years after grantsubject to the extent to which a performance condition has been achieved overthe initial three year period after the award is made and subject to therecipient's remaining in Cello's employment for a further year. There will be noability to retest this condition and vesting will also be conditional uponearnings per share increasing in each of the three years after the date ofgrant. For any awards made in the first year following the implementation of thePlan the performance condition will be based on Cello's compound annual growthin earnings per share in the three years following the date of grant as shownbelow:- - no awards will vest if the CAGR is less than 10 per cent. - 20 per cent of awards will vest if the CAGR is 10 per cent. - 100 per cent of awards will vest if the CAGR is 15 per cent or more - if the CAGR is between 10 and 15 per cent. the percentage of awards vesting will be determined on a straight line basis between 20 and 100 per cent. Changes to performance conditions. The Remuneration Committee may applydifferent conditions for future awards and may also vary the performanceconditions applying to existing awards, for example, to take account oftechnical events such as changes in accounting standards and treatments.However, in both cases, the Committee will consult with Cello's majorshareholders before doing so. Change of control. On a change of control of the company (or, if the Committeedetermines, in the case of a demerger) options will be exercisable subject tothe extent to which the performance conditions have been satisfied up to thedate of the event (taking account of the fact that the conditions will bemeasured over a shorter period than originally envisaged). On a change ofcontrol that occurs as a result of an internal reorganisation, awards will berolled over (unless the Committee determines otherwise). Leavers. Options will normally lapse if a participant leaves the company.However, in certain "good leaver" situations (such as death, illness, disabilityetc.), or in other exceptional circumstances, options will either (i) beexercisable early subject to the extent to which the Committee determines thatthe performance conditions have been satisfied at the relevant time (againtaking account of the fact that the conditions will be measured over a shorterperiod than originally envisaged) or (ii) remain unaffected and vest at the endof the original four year period, in both cases with a pro rata reduction insize (unless the Committee waives the requirement to pro rate awards). Life of the Plan. The Plan will have a ten year life, although the Committeewill review it after no more than five years. Grants of awards The Remuneration Committee expects shortly to make the first awards under thePlan at which time a further announcement will be made. 14 March 2006 Enquiries:Cello Group PLC 020 7457 2020Kevin Steeds, Chairman College Hill 020 7457 2020Adrian Duffield/Ben Way This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th Jun 20181:24 pmRNSBlock listing Interim Review
29th May 20183:45 pmRNSDirector/PDMR Dealings and Total Voting Rights
9th May 20181:14 pmRNSResult of AGM
9th May 20187:00 amRNSAGM Statement
30th Apr 20182:58 pmRNSTotal Voting Rights
26th Apr 20189:45 amRNSChange of Name
25th Apr 20184:45 pmRNSChange of Name update
23rd Apr 201810:28 amRNSChange of name to Cello Health Group plc
16th Apr 20189:30 amRNSAnnual Report and Notice of AGM
22nd Mar 20187:00 amRNSFinal Results
27th Feb 20183:38 pmRNSTotal Voting Rights
18th Jan 20187:00 amRNSPre Close Trading Statement
23rd Nov 20173:54 pmRNSHolding(s) in Company
31st Oct 201711:16 amRNSTotal Voting Rights
26th Oct 20172:37 pmRNSDirector/PDMR Shareholding
29th Sep 20173:43 pmRNSGrant of Options
27th Sep 20174:59 pmRNSDirector/PDMR Shareholding
22nd Sep 201712:05 pmRNSDirector/PDMR Shareholding
20th Sep 20173:58 pmRNSHolding(s) in Company
20th Sep 201711:52 amRNSAdditional Block Listing of Ordinary Shares
20th Sep 20177:00 amRNSInterim Results
31st Aug 20173:19 pmRNSTotal Voting Rights
31st Jul 20173:06 pmRNSTotal Voting Rights
19th Jul 20177:00 amRNSPre Close Trading Statement
18th Jul 20177:00 amRNSAcquisition of Advantage Healthcare Inc
30th Jun 201712:31 pmRNSTotal Voting Rights
23rd Jun 201712:23 pmRNSHolding(s) in Company
14th Jun 201711:33 amRNSDirector/PDMR Shareholding
31st May 201710:27 amRNSTotal Voting Rights
18th May 20172:13 pmRNSHolding(s) in Company
10th May 20175:18 pmRNSHolding(s) in Company
9th May 20172:55 pmRNSResult of AGM
9th May 20177:00 amRNSAGM Statement
2nd May 20173:15 pmRNSIssue of Equity
13th Apr 20172:40 pmRNSAnnual Report and notice of Annual General Meeting
4th Apr 20175:44 pmRNSBlock listing Interim Review
31st Mar 201710:43 amRNSTotal Voting Rights
28th Mar 20173:03 pmRNSHolding(s) in Company
22nd Mar 20177:00 amRNSPreliminary Results
21st Feb 20171:30 pmRNSHolding(s) in Company
20th Feb 20173:19 pmRNSHolding(s) in Company
20th Feb 20179:29 amRNSTotal Voting Rights
17th Feb 201710:40 amRNSResult of General Meeting
1st Feb 20177:00 amRNSPlacing & Acquisition of Defined Health
19th Jan 20177:00 amRNSPre close trading statement
31st Oct 20163:58 pmRNSTotal Voting Rights
28th Oct 201611:37 amRNSDirector/PDMR Shareholding
12th Oct 20167:00 amRNSDirectorate Change
5th Oct 20164:32 pmRNSDirector/PDMR Shareholding
23rd Sep 20165:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.